Uncategorised pages

Showing below up to 50 results starting with #1.

View (previous 50) (next 50) (20 | 50 | 100 | 250 | 500)

1. 2010-April-Guidelines for use of serum free light chain assays
2. 2010-Sep-Biology of immunoglobulin light chains
3. 2010-Sep-Cerebrospinal fluid and free light chains
4. 2010-Sep-Contents
5. 2010-Sep-Dedication and Acknowledgements
6. 2010-Sep-Dr Bence Jones and the history of free light chains
7. 2010-Sep-Implementation and interpretation of free light chain assays
8. 2010-Sep-Intact immunoglobulin MM (IIMM) - sFLCs at diagnosis
9. 2010-Sep-Intact immunoglobulin multiple myeloma (IIMM) - theoretical considerations of sFLC and Ig measurements
10. 2010-Sep-Introduction
11. 2010-Sep-Localised amyloid disease
12. 2010-Sep-Overview - The clinical importance of serum free light chain analysis
13. 2010-Sep-Preface to 1st edition 2003
14. 2010-Sep-Preface to 5th edition
15. 2010-Sep-Quality assurance for serum free light chain analysis
16. 2010-Sep-Sensitivity of serum free light chain assays
17. 2011-April-Guidelines for use of serum free light chain assays
18. 2011-March-Multiple myeloma - Introduction
19. AL Amyloidosis
20. APR-2012Cerebrospinal fluid and free light chains
21. APR-2012Contents
22. Abbreviations
23. Analysis of Ig heavy chain/light chain pairs (Hevylite™)
24. Apr-2012Nonsecretory multiple myeloma (NSMM)
25. Apr2012Contents
26. Asymptomatic (smouldering) multiple myeloma (ASMM)
27. Biology of immunoglobulin light chains
28. Cerebrospinal fluid and free light chains
29. Classification of diseases with increased immunoglobulins
30. Contents
31. Data:left
32. Data:right
33. Dec-2011-AL Amyloidosis
34. Dedication and Acknowledgements
35. Dr Bence Jones and the history of free light chains
36. FREELITE
37. Free light chains and monoclonal gammopathies
38. Guidelines for use of serum free light chain assays
39. HEVYLITE
40. Hevylite publications
41. Immune stimulation and elevated polyclonal free light chains
42. Immunoassays for free light chain measurement
43. Implementation and interpretation of free light chain assays
44. Important notice
45. Instrumentation for free light chain immunoassays
46. Intact immunoglobulin MM (IIMM) - sFLCs at diagnosis
47. Intact immunoglobulin multiple myeloma (IIMM) - theoretical considerations of sFLC and Ig measurements
48. Introduction
49. Light chain deposition disease (LCDD)
50. Light chain multiple myeloma (LCMM)

View (previous 50) (next 50) (20 | 50 | 100 | 250 | 500)